Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merrimack Receives $5M Milestone from Shire | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merrimack Receives $5M Milestone from Shire

Triggered by the sale of ONIVYDE in the first major non-European, non-Asian country

By: Betsy Louda

, Contract Pharma

Merrimack Pharmaceuticals has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack’s asset sale to Ipsen in 2017.

“Since the start of the third quarter, Merrimack has received $38 million in non-dilutive capital, including two milestone payments from Shire totaling $23 million,” said Richard Peters, M.D., Ph.D., president and chief executive officer of Merrimack. “We are pleased to further strengthen the Company’s cash position as we continue advancing our wholly-owned clinical and preclinical pipeline.”

The terms of the Company’s asset sale to Ipsen in 2017 entitled Merrimack to receive up to an aggregate of $33 million in net milestone payments from Shire, of which Merrimack has now received $23 million, including this milestone and the $18 million payment in August 2018 resulting from the sale of ONIVYDE in two additional major European countries. Merrimack remains eligible to receive up to an additional $10 million in milestone payments for the first patient dosed in a pivotal clinical trial of ONIVYDE in an indication other than pancreatic cancer.

Furthermore, Merrimack is entitled to receive up to an aggregate of $450 million in regulatory-based milestones from Ipsen. Merrimack has stated it expects to pass these proceeds through to stockholders, net of any taxes owed and subject to there being a sufficient surplus at that time, consisting of: 

  • $225 million upon approval by the FDA of ONIVYDE for the first-line treatment of metastatic adenocarcinoma of the pancreas, subject to certain conditions; 
  • $150 million upon approval by the FDA of ONIVYDE for the treatment of small cell lung cancer after failure of first-line chemotherapy; and 
  • $75 million upon approval by the FDA of ONIVYDE for an additional indication unrelated to those described above.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters